Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Leptin, a hormone produced by fat cells, is crucial for regulating energy equilibrium, managing body mass, and influencing metabolic and cardiovascular well-being. Leptin decreases appetite, boosts energy usage, and has a significant impact on glucose metabolism by primarily activating the JAK2/STAT3 signaling pathway in the hypothalamus. Obesity leads to the development of leptin resistance, which is marked by high levels of leptin in the bloodstream and a decreased responsiveness to its signals. This leads to increased food consumption, weight gain, and metabolic issues, such as type 2 diabetes (T2DM) and cardiovascular disease (CVD). This study explores the many roles of leptin in metabolic regulation, with a specific emphasis on its interaction with insulin and its impact on peripheral organs like the pancreas, liver, and muscles. Leptin resistance worsens chronic inflammation, oxidative stress, endothelial dysfunction, and insulin resistance, all of which are strongly linked to the development of cardiovascular disease (CVD). Moreover, there is a correlation between genetic variations in the leptin receptor (LEPR) gene and a higher susceptibility to stroke and other cardiovascular issues. Therapeutic interventions, such as leptin replacement therapy, have demonstrated potential in the treatment of congenital leptin insufficiency and lipodystrophy while also enhancing glycaemic control, lipid profiles, and neuroendocrine function. Recent studies have indicated that manipulating leptin levels or enhancing its responsiveness by specific treatments, such as chemical chaperones and inhibitors of negative regulators like SOCS3 and PTP1B, might potentially restore the efficacy of leptin.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X356019250118170444
2025-02-07
2025-10-05

  • From This Site

    /content/journals/ccr/10.2174/011573403X356019250118170444
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhaoS. KusminskiC.M. SchererP.E. Adiponectin, leptin and cardiovascular disorders.Circ. Res.2021128113614910.1161/CIRCRESAHA.120.31445833411633
     [Google Scholar]
  2. ZhaoS. KusminskiC.M. ElmquistJ.K. SchererP.E. Leptin: Less is more.Diabetes202069582382910.2337/dbi19‑001832312898
     [Google Scholar]
  3. WelshA. HammadM. PiñaI.L. KulinskiJ. Obesity and cardiovascular health.Eur. J. Prev. Cardiol.20243181026103510.1093/eurjpc/zwae02538243826
     [Google Scholar]
  4. WaumanJ. ZabeauL. TavernierJ. The leptin receptor complex: Heavier than expected?Front. Endocrinol.201783010.3389/fendo.2017.0003028270795
     [Google Scholar]
  5. WasimM. AwanF.R. NajamS.S. KhanA.R. KhanH.N. Role of leptin deficiency, inefficiency, and leptin receptors in obesity.Biochem. Genet.201654556557210.1007/s10528‑016‑9751‑z27313173
     [Google Scholar]
  6. AnjumT. ArifZ. DarM. RazaA. BibiZ. Leptin: Mechanisms involved in signaling and resistance.J. Pharm. Res. & Rep.2021212410.47363/JPRSR/2021(2)123
     [Google Scholar]
  7. AnthonyS.R. GuarnieriA.R. GozdiffA. HelsleyR.N. OwensP.A.III TranterM. Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis.Clin. Sci. (Lond.)2019133222329234410.1042/CS2019057831777927
     [Google Scholar]
  8. GarcíaV.T. GonzálezP.M. PérezP.A. RibaltaJ. ArrietaF. AguilarM. ObayaJ. OrnaG.J. IglesiasP. NavarroJ. DuránS. BotetP.J. MargaletS.V. Role of leptin in obesity, cardiovascular disease, and type 2 diabetes.Int. J. Mol. Sci.2024254233810.3390/ijms2504233838397015
     [Google Scholar]
  9. RamanP. KhanalS. Leptin in atherosclerosis: Focus on macrophages, endothelial and smooth muscle cells.Int. J. Mol. Sci.20212211544610.3390/ijms2211544634064112
     [Google Scholar]
  10. SöderbergS. StegmayrB. GladerA.C. BirganderS.L. AhrénB. OlssonT. High leptin levels are associated with stroke.Cerebrovasc. Dis.2003151-2636910.1159/00006712812499713
     [Google Scholar]
  11. AminM.N. HussainM.S. SarwarM.S. MoghalR.M.M. DasA. HossainM.Z. ChowdhuryJ.A. MillatM.S. IslamM.S. How the association between obesity and inflammation may lead to insulin resistance and cancer.Diabetes Metab. Syndr.20191321213122410.1016/j.dsx.2019.01.04131336467
     [Google Scholar]
  12. TsaiJ.P. WangJ.H. ChenM.L. YangC.F. ChenY.C. HsuB.G. Association of serum leptin levels with central arterial stiffness in coronary artery disease patients.BMC Cardiovasc. Disord.20161618010.1186/s12872‑016‑0268‑527151106
     [Google Scholar]
  13. WangC. ChangL. WangJ. XiaL. CaoL. WangW. XuJ. GaoH. Leptin and risk factors for atherosclerosis: A review.Medicine202310246e3607610.1097/MD.000000000003607637986371
     [Google Scholar]
  14. MoutonA.J. LiX. HallM.E. HallJ.E. Obesity, hypertension, and cardiac dysfunction: Novel roles of immunometabolism in macrophage activation and inflammation.Circ. Res.2020126678980610.1161/CIRCRESAHA.119.31232132163341
     [Google Scholar]
  15. KangK.W. OkM. LeeS.K. Leptin as a key between obesity and cardiovascular disease.J. Obes. Metab. Syndr.202029424825910.7570/jomes2012033342767
     [Google Scholar]
  16. MolléN. KrichevskyS. KermaniP. SilverR.T. RitchieE. ScanduraJ.M. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.Blood202013513blood.201900305010.1182/blood.201900305032047890
     [Google Scholar]
  17. LiuH. DuT. LiC. YangG. STAT3 phosphorylation in central leptin resistance.Nutr. Metab.20211813910.1186/s12986‑021‑00569‑w33849593
     [Google Scholar]
  18. OrnellasF. MelloS.V. Mandarim-de-LacerdaC.A. AguilaM.B. Combined parental obesity augments single-parent obesity effects on hypothalamus inflammation, leptin signaling (JAK/STAT), hyperphagia, and obesity in the adult mice offspring.Physiol. Behav.2016153475510.1016/j.physbeh.2015.10.01926485293
     [Google Scholar]
  19. LiuZ. GanL. ZhouZ. JinW. SunC. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte.Immunobiology2015220894795310.1016/j.imbio.2015.02.00425720636
     [Google Scholar]
  20. GenchiV.A. D’OriaR. PalmaG. CaccioppoliC. CignarelliA. NatalicchioA. LaviolaL. GiorginoF. PerriniS. Impaired leptin signalling in obesity: Is leptin a new thermolipokine?Int. J. Mol. Sci.20212212644510.3390/ijms2212644534208585
     [Google Scholar]
  21. MacedoT.J.S. MenezesV.G. BarberinoR.S. SilvaR.L.S. GouveiaB.B. MonteA.P.O. LinsT.L.B.G. SantosJ.M.S. BezerraM.É.S. WischralA. QueirozM.A.A. AraújoG.G.L. BatistaA.M. MatosM.H.T. Leptin decreases apoptosis and promotes the activation of primordial follicles through the phosphatidylinositol-3-kinase/protein kinase B pathway in cultured ovine ovarian tissue.Zygote202129644545110.1017/S096719942100003433906701
     [Google Scholar]
  22. SáinzN. NavarroG.C.J. MartínezJ.A. AliagaM.M.J. Leptin signaling as a therapeutic target of obesity.Expert Opin. Ther. Targets201519789390910.1517/14728222.2015.101882425726860
     [Google Scholar]
  23. QuartaC. GarridoS.M.A. TschöpM.H. ClemmensenC. Renaissance of leptin for obesity therapy.Diabetologia201659592092710.1007/s00125‑016‑3906‑726983921
     [Google Scholar]
  24. RehmanK. AkashM.S.H. AlinaZ. Leptin: A new therapeutic target for treatment of diabetes mellitus.J. Cell. Biochem.201811975016502710.1002/jcb.2658029236298
     [Google Scholar]
  25. D’souzaA.M. NeumannU.H. GlavasM.M. KiefferT.J. The glucoregulatory actions of leptin.Mol. Metab.2017691052106510.1016/j.molmet.2017.04.01128951828
     [Google Scholar]
  26. RecinellaL. OrlandoG. FerranteC. ChiavaroliA. BrunettiL. LeoneS. Adipokines: New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases.Front. Physiol.20201157896610.3389/fphys.2020.57896633192583
     [Google Scholar]
  27. FilhoP.G. MastronardiC.A. LicinioJ. Leptin treatment: Facts and expectations.Metabolism201564114615610.1016/j.metabol.2014.07.01425156686
     [Google Scholar]
  28. LoboR.A.M. DonatoJ.Jr The role of leptin in health and disease.Temperature20174325829110.1080/23328940.2017.132700328944270
     [Google Scholar]
  29. RussoB. MenduniM. BorboniP. PicconiF. FrontoniS. Autonomic nervous system in obesity and insulin-resistance—The complex interplay between leptin and central nervous system.Int. J. Mol. Sci.20212210518710.3390/ijms2210518734068919
     [Google Scholar]
  30. RoobanS. SenghorA.K.A. VinodhiniV.M. KumarJ.S. Adropin: A crucial regulator of cardiovascular health and metabolic balance.Metab. Open20242310029910.1016/j.metop.2024.10029939045137
     [Google Scholar]
  31. SáinzN. BarrenetxeJ. AliagaM.M.J. MartínezJ.A. Leptin resistance and diet-induced obesity: Central and peripheral actions of leptin.Metabolism2015641354610.1016/j.metabol.2014.10.01525497342
     [Google Scholar]
  32. FriedmanJ. The long road to leptin.J. Clin. Invest.2016126124727473410.1172/JCI9157827906690
     [Google Scholar]
  33. DasS. Effect of obesity in the cardiovascular system.Obesity and its Impact on Health2021679010.1007/978‑981‑33‑6408‑0_6
     [Google Scholar]
  34. FarkhondehT. LlorensS. ShahriP.A.M. AshrafizadehM. TalebiM. ShakibaeiM. SamarghandianS. An overview of the role of adipokines in cardiometabolic diseases.Molecules20202521521810.3390/molecules2521521833182462
     [Google Scholar]
  35. AlbarracínG.M.L. TorresF.A.Y. Adiponectin and leptin adipocytokines in metabolic syndrome: What is its importance?Dubai Diabetes Endocrinol. J.20202639310210.1159/000510521
     [Google Scholar]
  36. DessieG. AyelignB. AkaluY. ShibabawT. MollaM.D. Effect of leptin on chronic inflammatory disorders: Insights to therapeutic target to prevent further cardiovascular complication.Diabetes Metab. Syndr. Obes.2021143307332210.2147/DMSO.S32131134305402
     [Google Scholar]
  37. FriedmanJ.M. Leptin and the endocrine control of energy balance.Nat. Metab.20191875476410.1038/s42255‑019‑0095‑y32694767
     [Google Scholar]
  38. InoueD.S. PanissaV.L. AntunesB.M. OliveiraF.P. MaltaR.B. CaldeiraR.S. CamposE.Z. PimentelG.D. FranchiniE. LiraF.S. Reduced leptin level is independent of fat mass changes and hunger scores from high-intensity intermittent plus strength training.J. Sports Med. Phys. Fitness2018587-81045105110.23736/S0022‑4707.17.07370‑428488831
     [Google Scholar]
  39. HwangJ. YooJ.A. YoonH. HanT. YoonJ. AnS. ChoJ.Y. LeeJ. The role of leptin in the association between obesity and psoriasis.Biomol. Ther.2021291112110.4062/biomolther.2020.05432690821
     [Google Scholar]
  40. JumliM.N. NadeemM.I. The mechanistic and pathophysiological role of adiponectin and resistin towards regulation of food intake and appetite in cardiovascular associated risk factor of metabolic syndrome 2021
     [Google Scholar]
  41. LeDucC.A. SkowronskiA.A. RosenbaumM. The role of leptin in the development of energy homeostatic systems and the maintenance of body weight.Front. Physiol.20211278951910.3389/fphys.2021.78951934955895
     [Google Scholar]
  42. LukitoA.A. BakriS. KaboP. WijayaA. The mechanism of coronary artery calcification in centrally obese non-diabetic men: Study on the interaction of leptin, free leptin index, adiponectin, hs-C reactive protein, bone morphogenetic protein-2 and matrix Gla protein.Mol. Cel. Biom. Sci.202042889310.21705/mcbs.v4i2.104
     [Google Scholar]
  43. MinoisB.J.B. TrousselardM. ThivelD. BensonA.C. SchmidtJ. MoustafaF. BouvierD. DutheilF. Leptin as a biomarker of stress: A systematic review and meta-analysis.Nutrients20211310335010.3390/nu1310335034684349
     [Google Scholar]
  44. BlancoA.M. SoengasJ.L. Leptin signalling in teleost fish with emphasis in food intake regulation.Mol. Cell. Endocrinol.202152611120910.1016/j.mce.2021.11120933588023
     [Google Scholar]
  45. OliveiraV. KwitekA.E. SigmundC.D. MorselliL.L. GrobeJ.L. Recent advances in hypertension: Intersection of metabolic and blood pressure regulatory circuits in the central nervous system.Hypertension20217741061106810.1161/HYPERTENSIONAHA.120.1451333611936
     [Google Scholar]
  46. MünzbergH. SinghP. HeymsfieldS.B. YuS. MorrisonC.D. Recent advances in understanding the role of leptin in energy homeostasis.F1000 Res.2020945110.12688/f1000research.24260.132518627
     [Google Scholar]
  47. ObradovicM. MilovanovicS.E. SoskicS. EssackM. AryaS. StewartA.J. GojoboriT. IsenovicE.R. Leptin and obesity: Role and clinical implication.Front. Endocrinol.20211258588710.3389/fendo.2021.58588734084149
     [Google Scholar]
  48. PerakakisN. FarrO.M. MantzorosC.S. Leptin in leanness and obesity: JACC state-of-the-art review.J. Am. Coll. Cardiol.202177674576010.1016/j.jacc.2020.11.06933573745
     [Google Scholar]
  49. PereiraS. ClineD.L. GlavasM.M. CoveyS.D. KiefferT.J. Tissue-specific effects of leptin on glucose and lipid metabolism.Endocr. Rev.202142112810.1210/endrev/bnaa02733150398
     [Google Scholar]
  50. PérezP.A. GarcíaV.T. RiejosF.P. GonzálezM.J. EgeaS.J.J. MargaletS.V. Role of leptin as a link between metabolism and the immune system.Cytokine Growth Factor Rev.201735718410.1016/j.cytogfr.2017.03.00128285098
     [Google Scholar]
  51. RahmaniA. ToloueitabarY. MohsenzadehY. HemmatiR. SayehmiriK. AsadollahiK. Association between plasma leptin/adiponectin ratios with the extent and severity of coronary artery disease.BMC Cardiovasc. Disord.202020147410.1186/s12872‑020‑01723‑733148166
     [Google Scholar]
  52. RahmouniK. HaynesW.G. Leptin and the cardiovascular system.Recent Prog. Horm. Res.200459122524410.1210/rp.59.1.22514749504
     [Google Scholar]
  53. PanW.W. MyersM.G.Jr Leptin and the maintenance of elevated body weight.Nat. Rev. Neurosci.20181929510510.1038/nrn.2017.16829321684
     [Google Scholar]
  54. SaeedB.A.A. AlsalkhiH.a. KasimS.E. RgeebA.N. QasimM. Impact of Leptin Hormone on Cardiac Function in a Sample of Iraqi Population with cardiovascular disease.Inter. J. Pharma. Res.202012409752366
     [Google Scholar]
  55. SenesiP. LuziL. TerruzziI. Adipokines, myokines, and cardiokines: The role of nutritional interventions.Int. J. Mol. Sci.20202121837210.3390/ijms2121837233171610
     [Google Scholar]
  56. SweeneyG. Cardiovascular effects of leptin.Nat. Rev. Cardiol.201071222910.1038/nrcardio.2009.22419949425
     [Google Scholar]
  57. SocolC.T. ChiraA. SanchezM.M.A. SanchezN.M.A. MaerescuC.M. MierlitaD. RusuA.V. AlcarazR.A.J. TrifM. MolinaR.B. Leptin signaling in obesity and colorectal cancer.Int. J. Mol. Sci.2022239471310.3390/ijms2309471335563103
     [Google Scholar]
  58. NaylorC. PetriW.A.Jr Leptin regulation of immune responses.Trends Mol. Med.2016222889810.1016/j.molmed.2015.12.00126776093
     [Google Scholar]
  59. NoordamR. BoersmaV. VerkouterI. Cessiel.S. ChristenT. LambH.J. RosendaalF.R. Willems van DijkK. Heemstv.D. Mutsertd.R. The role of C-reactive protein, adiponectin and leptin in the association between abdominal adiposity and insulin resistance in middle-aged individuals.Nutr. Metab. Cardiovasc. Dis.20203081306131410.1016/j.numecd.2020.04.02132507340
     [Google Scholar]
  60. MosavatM. MirsanjariM. ArabiatD. SmythA. WhiteheadL. The role of sleep curtailment on leptin levels in obesity and diabetes mellitus.Obes. Facts202114221422110.1159/00051409533756469
     [Google Scholar]
  61. TrinhT. BroxmeyerH.E. Role for leptin and leptin receptors in stem cells during health and diseases.Stem Cell Rev. Rep.202117251152210.1007/s12015‑021‑10132‑y33598894
     [Google Scholar]
  62. MischM. PuthanveetilP. The head-to-toe hormone: Leptin as an extensive modulator of physiologic systems.Int. J. Mol. Sci.20222310543910.3390/ijms2310543935628271
     [Google Scholar]
  63. CuevasG.J. RodriguezS.A. RiosM.A. RamírezM.H.C. MorenoG.M. BañuelosG.J. SantosA. BorundaA.J. Molecular mechanisms of obesity-linked cardiac dysfunction: An up-date on current knowledge.Cells202110362910.3390/cells1003062933809061
     [Google Scholar]
  64. HallJ.E. MoutonA.J. Silvad.A.A. OmotoA.C.M. WangZ. LiX. Carmod.J.M. Obesity, kidney dysfunction, and inflammation: Interactions in hypertension.Cardiovasc. Res.202111781859187610.1093/cvr/cvaa33633258945
     [Google Scholar]
  65. HallM.E. HarmanceyR. StecD.E. Lean heart: Role of leptin in cardiac hypertrophy and metabolism.World J. Cardiol.20157951152410.4330/wjc.v7.i9.51126413228
     [Google Scholar]
  66. KamareddineL. GhantousC.M. AllouchS. AshmarA.S.A. AnlarG. KannanS. DjouhriL. KorashyH.M. AgouniA. ZeidanA. Between inflammation and autophagy: The role of leptin-adiponectin axis in cardiac remodeling.J. Inflamm. Res.2021145349536510.2147/JIR.S32223134703273
     [Google Scholar]
  67. LandechoM.F. TueroC. ValentíV. BilbaoI. de la HigueraM. FrühbeckG. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk.Nutrients20191111266410.3390/nu1111266431694146
     [Google Scholar]
  68. KönnerA.C. BrüningJ.C. Selective insulin and leptin resistance in metabolic disorders.Cell Metab.201216214415210.1016/j.cmet.2012.07.00422883229
     [Google Scholar]
  69. DavisJ.F. ChoiD.L. BenoitS.C. Insulin, leptin and reward.Trends Endocrinol. Metab.2010212687410.1016/j.tem.2009.08.00419818643
     [Google Scholar]
  70. ZhangZ.Y. DoddG.T. TiganisT. Protein tyrosine phosphatases in hypothalamic insulin and leptin signaling.Trends Pharmacol. Sci.2015361066167410.1016/j.tips.2015.07.00326435211
     [Google Scholar]
  71. AmitaniM. AsakawaA. AmitaniH. InuiA. The role of leptin in the control of insulin-glucose axis.Front. Neurosci.201375110.3389/fnins.2013.0005123579596
     [Google Scholar]
  72. RodríguezA. CatalánV. AmbrosiG.J. NavarroG.S. RotellarF. ValentíV. SilvaC. GilM.J. SalvadorJ. BurrellM.A. CalamitaG. MalagónM.M. FrühbeckG. Insulin- and leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade.J. Clin. Endocrinol. Metab.2011964E586E59710.1210/jc.2010‑140821289260
     [Google Scholar]
  73. FieldsD.A. DemerathE.W. Relationship of insulin, glucose, leptin, IL ‐6 and TNF ‐α in human breast milk with infant growth and body composition.Pediatr. Obes.20127430431210.1111/j.2047‑6310.2012.00059.x22577092
     [Google Scholar]
  74. LeisegangK. BouicP.J.D. MenkveldR. HenkelR.R. Obesity is associated with increased seminal insulin and leptin alongside reduced fertility parameters in a controlled male cohort.Reprod. Biol. Endocrinol.20141213410.1186/1477‑7827‑12‑3424885899
     [Google Scholar]
  75. BelgardtB.F. BrüningJ.C. CNS leptin and insulin action in the control of energy homeostasis.Ann. N. Y. Acad. Sci.2010121219711310.1111/j.1749‑6632.2010.05799.x21070248
     [Google Scholar]
  76. WangM. ChenL. ClarkG.O. LeeY. StevensR.D. IlkayevaO.R. WennerB.R. BainJ.R. CharronM.J. NewgardC.B. UngerR.H. Leptin therapy in insulin-deficient type I diabetes.Proc. Natl. Acad. Sci. USA2010107114813481910.1073/pnas.090942210720194735
     [Google Scholar]
  77. SheblT. AzeemN.E.D.A. YounisH.A. SolimanA.M. AshmawyA.M. AliN.M.M. Relationship between serum leptin concentration and insulin resistance syndrome in patients with type 2 diabetes mellitus.J. Cur. Med. Res. Pract.20172212513210.4103/JCMRP.JCMRP_33_16
     [Google Scholar]
  78. GhadgeA.A. KhaireA.A. Leptin as a predictive marker for metabolic syndrome.Cytokine201912115473510.1016/j.cyto.2019.15473531154250
     [Google Scholar]
  79. DePaoliA.M. 20 YEARS OF LEPTIN: Leptin in common obesity and associated disorders of metabolism.J. Endocrinol.20142231T71T8110.1530/JOE‑14‑025824973357
     [Google Scholar]
  80. KatsikiN. MikhailidisD.P. BanachM. Leptin, cardiovascular diseases and type 2 diabetes mellitus.Acta Pharmacol. Sin.20183971176118810.1038/aps.2018.4029877321
     [Google Scholar]
  81. MarescaF. PalmaV.D. BevilacquaM. UccelloG. TaglialatelaV. GiaquintoA. EspositoG. TrimarcoB. CirilloP. Adipokines, vascular wall, and cardiovascular disease: A focused overview of the role of adipokines in the pathophysiology of cardiovascular disease.Angiology201566182410.1177/000331971352046324535638
     [Google Scholar]
  82. PuurunenV.P. KiviniemiA. LepojärviS. PiiraO.P. HedbergP. JunttilaJ. UkkolaO. HuikuriH. Leptin predicts short-term major adverse cardiac events in patients with coronary artery disease.Ann. Med.201749544845410.1080/07853890.2017.130167828300429
     [Google Scholar]
  83. VandervleutenG. VeerkampM. VantitsL. ToenhakeH. DenheijerM. StalenhoefA. DegraafJ. Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD.Atherosclerosis2005183235536010.1016/j.atherosclerosis.2005.03.01916285998
     [Google Scholar]
  84. RaginoY.I. StakhnevaE.M. PolonskayaY.V. KashtanovaE.V. The role of secretory activity molecules of visceral adipocytes in abdominal obesity in the development of cardiovascular disease: A review.Biomolecules202010337410.3390/biom1003037432121175
     [Google Scholar]
  85. LekvaT. MichelsenA.E. AukrustP. HenriksenT. BollerslevJ. UelandT. Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus.Cardiovasc. Diabetol.2017161510.1186/s12933‑016‑0492‑428068986
     [Google Scholar]
  86. VavruchC. LänneT. FredriksonM. LindströmT. ÖstgrenC.J. NystromF.H. Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes.Cardiovasc. Diabetol.20151416210.1186/s12933‑015‑0208‑125994184
     [Google Scholar]
  87. BaroneI. GiordanoC. BonofiglioD. AndòS. CatalanoS. Leptin, obesity and breast cancer: Progress to understanding the molecular connections.Curr. Opin. Pharmacol.201631838910.1016/j.coph.2016.10.00327816025
     [Google Scholar]
  88. MikamiK. EndoT. SawadaN. IgarashiG. KimuraM. HasegawaT. IinoC. TomitaH. SawadaK. NakajiS. MatsuzakaM. TorokN.J. FukudaS. Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population.Cytokine202012615492710.1016/j.cyto.2019.15492731756645
     [Google Scholar]
  89. AhianteB.O. SmithW. LammertynL. SchutteA.E. Leptin and the vasculature in young adults: The African‐ PREDICT study.Eur. J. Clin. Invest.2019491e1303910.1111/eci.1303930347447
     [Google Scholar]
  90. GhantousC.M. AzrakZ. HanacheS. KheirA.W. ZeidanA. Differential role of leptin and adiponectin in cardiovascular system.Int. J. Endocrinol.20152015111310.1155/2015/53432026064110
     [Google Scholar]
  91. BattineniG. SagaroG.G. ChintalapudiN. AmentaF. TomassoniD. TayebatiS.K. Impact of obesity-induced inflammation on cardiovascular diseases (CVD).Int. J. Mol. Sci.2021229479810.3390/ijms2209479833946540
     [Google Scholar]
  92. UñaM.M. MancheñoL.Y. DiéguezC. RojoF.M.A. NovelleM.G. Unraveling the role of leptin in liver function and its relationship with liver diseases.Int. J. Mol. Sci.20202124936810.3390/ijms2124936833316927
     [Google Scholar]
  93. SabbatiniA.R. FontanaV. LaurentS. MorenoH. An update on the role of adipokines in arterial stiffness and hypertension.J. Hypertens.201533343544410.1097/HJH.000000000000044425502905
     [Google Scholar]
  94. NowzariZ. MasoumiM. RobatiN.M. AkbariH. ShahrokhiN. AsadikaramG. Association of polymorphisms of leptin, leptin receptor and apelin receptor genes with susceptibility to coronary artery disease and hypertension.Life Sci.201820716617110.1016/j.lfs.2018.06.00729883719
     [Google Scholar]
  95. LuS.C. AkanjiA.O. Leptin, obesity, and hypertension: A review of pathogenetic mechanisms.Metab. Syndr. Relat. Disord.202018939940510.1089/met.2020.006532876506
     [Google Scholar]
  96. BlüherM. MantzorosC.S. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century.Metabolism201564113114510.1016/j.metabol.2014.10.01625497344
     [Google Scholar]
  97. SevenE. HusemoenL.L.N. SehestedT.S.G. IbsenH. WachtellK. LinnebergA. JeppesenJ.L. Adipocytokines, C-reactive protein, and cardiovascular disease: A population-based prospective study.PLoS One2015106e012898710.1371/journal.pone.012898726035431
     [Google Scholar]
  98. TsaiJ.P. The association of serum leptin levels with metabolic diseases.Tzu-Chi Med. J.201729419219610.4103/tcmj.tcmj_123_1729296046
     [Google Scholar]
  99. ShinM.K. ErasoC.C. MuY.P. GuC. YeungB.H.Y. KimL.J. LiuX.R. WuZ.J. PaudelO. PichardL.E. ShirahataM. TangW.Y. ShamJ.S.K. PolotskyV.Y. Leptin induces hypertension acting on transient receptor potential melastatin 7 channel in the carotid body.Circ. Res.201912511989100210.1161/CIRCRESAHA.119.31533831545149
     [Google Scholar]
  100. KimL.J. PolotskyV.Y. Carotid body and metabolic syndrome: Mechanisms and potential therapeutic targets.Int. J. Mol. Sci.20202114511710.3390/ijms2114511732698380
     [Google Scholar]
  101. SacramentoJ.F. AndrzejewskiK. MeloB.F. RibeiroM.J. ObesoA. CondeS.V. Exploring the mediators that promote carotid body dysfunction in type 2 diabetes and obesity related syndromes.Int. J. Mol. Sci.20202115554510.3390/ijms2115554532756352
     [Google Scholar]
  102. ParvanovaA. ReseghettiE. AbbateM. RuggenentiP. Mechanisms and treatment of obesity-related hypertension—Part 1: Mechanisms.Clin. Kidney J.2024171sfad28210.1093/ckj/sfad28238186879
     [Google Scholar]
  103. AmorimM.R. AungO. MokhlesiB. PolotskyV.Y. Leptin-mediated neural targets in obesity hypoventilation syndrome.Sleep2022459zsac15310.1093/sleep/zsac15335778900
     [Google Scholar]
  104. GuyenetP.G. StornettaR.L. SouzaG.M.P.R. AbbottS.B.G. BrooksV.L. Neuronal networks in hypertension: Recent advances.Hypertension202076230031110.1161/HYPERTENSIONAHA.120.1452132594802
     [Google Scholar]
  105. IturriagaR. AlcayagaJ. ChapleauM.W. SomersV.K. Carotid body chemoreceptors: Physiology, pathology, and implications for health and disease.Physiol. Rev.202110131177123510.1152/physrev.00039.201933570461
     [Google Scholar]
  106. FreireC. KimL.J. PolotskyV.Y. Pharmacologic Intervention Studies to Mitigate Breathing Instability–Animal Studies 202210.1201/9781003000631‑24
     [Google Scholar]
  107. CasadoM.E. PérezC.R. FragoL.M. BarriosV. Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies.Int. J. Mol. Sci.2023242142210.3390/ijms2402142236674935
     [Google Scholar]
  108. LavensD. On the role of SOCS proteins in leptin signalling.Ghent University2006
     [Google Scholar]
  109. OlofssonL.E. UngerE.K. CheungC.C. XuA.W. Modulation of AgRP-neuronal function by SOCS3 as an initiating event in diet-induced hypothalamic leptin resistance.Proc. Natl. Acad. Sci. USA20131108E697E70610.1073/pnas.121828411023386726
     [Google Scholar]
  110. PedrosoJ.A.B. BuonfiglioD.C. CardinaliL.I. FurigoI.C. LoboR.A.M. TirapeguiJ. EliasC.F. DonatoJ.Jr Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity.Mol. Metab.20143660861810.1016/j.molmet.2014.06.00125161884
     [Google Scholar]
  111. YangZ. HulverM. McMillanR.P. CaiL. KershawE.E. YuL. XueB. ShiH. Regulation of insulin and leptin signaling by muscle suppressor of cytokine signaling 3 (SOCS3).PLoS One2012710e4749310.1371/journal.pone.004749323115649
     [Google Scholar]
  112. WunderlichC.M. HövelmeyerN. WunderlichF.T. Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity.JAK-STAT201322e2387810.4161/jkst.2387824058813
     [Google Scholar]
  113. ZampieriT.T. LoboR.A.M. FurigoI.C. PedrosoJ.A.B. BuonfiglioD.C. DonatoJ.Jr SOCS3 deficiency in leptin receptor-expressing cells mitigates the development of pregnancy-induced metabolic changes.Mol. Metab.20154323724510.1016/j.molmet.2014.12.00525737950
     [Google Scholar]
  114. LiuJ. YangX. YuS. ZhengR. The leptin resistance.Neural Regulation of Metabolism2018145163
     [Google Scholar]
  115. HarlanS.M. RahmouniK. PI3K signaling: A key pathway in the control of sympathetic traffic and arterial pressure by leptin.Mol. Metab.201322697310.1016/j.molmet.2013.03.00424199153
     [Google Scholar]
  116. YamamotoN. TanidaM. KasaharaR. SobueK. SuzukiK. Leptin inhibits amyloid β‐protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway.J. Neurochem.2014131332333210.1111/jnc.1282825039425
     [Google Scholar]
  117. ModzelewskaP. ChludzinskaS. LewkoJ. ReszecJ. The influence of leptin on the process of carcinogenesis.Cont. Oncol.2019232636810.5114/wo.2019.85877
     [Google Scholar]
  118. HaglundE. NguyenL. SchaferN.P. LammertH. JenningsP.A. OnuchicJ.N. Uncovering the molecular mechanisms behind disease-associated leptin variants.J. Biol. Chem.201829333129191293310.1074/jbc.RA118.00395729950524
     [Google Scholar]
  119. MarquesV. ArellaF. AfonsoM.B. SantosA.A. RodriguesC.M.P. Decoding the role of leptin and adiponectin in obesity-related gastrointestinal cancer.Clin. Sci.2023137151095111410.1042/CS2023041137530554
     [Google Scholar]
  120. FengH. ZhengL. FengZ. ZhaoY. ZhangN. The role of leptin in obesity and the potential for leptin replacement therapy.Endocrine2013441333910.1007/s12020‑012‑9865‑y23274948
     [Google Scholar]
  121. GrecoM. SantoD.M. ComandèA. BelsitoE.L. AndòS. LiguoriA. LeggioA. Leptin-activity modulators and their potential pharmaceutical applications.Biomolecules2021117104510.3390/biom1107104534356668
     [Google Scholar]
  122. CalcaterraV. MagenesV.C. RossiV. FabianoV. MameliC. ZuccottiG. Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy.Pharmacol. Res.202318710662910.1016/j.phrs.2022.10662936566927
     [Google Scholar]
  123. ÖzenS. AkıncıB. OralE.A. Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people.J. Clin. Res. Pediatr. Endocrinol.2020121172810.4274/jcrpe.galenos.2019.2019.012431434462
     [Google Scholar]
  124. PengJ. YinL. WangX. Central and peripheral leptin resistance in obesity and improvements of exercise.Horm. Behav.202113310500610.1016/j.yhbeh.2021.10500634087669
     [Google Scholar]
  125. Akeel Al-hussaniyH. AlburghaifH.A. NajiA.M. Leptin hormone and its effectiveness in reproduction, metabolism, immunity, diabetes, hopes and ambitions.J. Med. Life202114560060510.25122/jml‑2021‑015335027962
     [Google Scholar]
  126. FreitasI.N. Silvad.J.A.Jr OliveiraK.M. AlvesL.B. Dos Reis AraújoT. CamporezJ.P. CarneiroE.M. DavelA.P. Insights by which TUDCA is a potential therapy against adiposity.Front. Endocrinol.202314109003910.3389/fendo.2023.109003936896173
     [Google Scholar]
  127. SuriagandhiV. NachiappanV. Therapeutic target analysis and molecular mechanism of melatonin-treated leptin resistance induced obesity: A Systematic Study of Network Pharmacology.Front. Endocrinol.20221392757610.3389/fendo.2022.92757635937803
     [Google Scholar]
  128. IsodaM. EbiharaK. SawayamaN. MurakamiA. EbiharaC. ShibuyaK. TakeiA. TakeiS. WakabayashiT. YamamuroD. TakahashiM. NagashimaS. IshibashiS. Leptin sensitizing effect of 1,3-butanediol and its potential mechanism.Sci. Rep.20211111769110.1038/s41598‑021‑96460‑y34489483
     [Google Scholar]
  129. RoyP.K. IslamJ. LalhlenmawiaH. Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance.Egypt. Heart J.20237512410.1186/s43044‑023‑00352‑737014444
     [Google Scholar]
  130. PanicoG. FascioloG. MigliaccioV. MatteisD.R. LionettiL. NapolitanoG. AgnisolaC. VendittiP. LombardiA. 1,3-Butanediol administration increases β-hydroxybutyrate plasma levels and affects redox homeostasis, endoplasmic reticulum stress, and adipokine production in rat gonadal adipose tissue.Antioxidants2023127147110.3390/antiox1207147137508009
     [Google Scholar]
  131. ChristoffersenB.Ø. DelgadoS.G. JohnL.M. RyanD.H. RaunK. RavussinE. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss.Obesity202230484185710.1002/oby.2337435333444
     [Google Scholar]
  132. NelderM. The role of an addictive tendency towards food and patterns of body fat distribution in obesity and metabolic health.Memorial University of NewfoundlandCanada2020
     [Google Scholar]
  133. JoyL.Y. Molecular Mechanisms of Appetite and Energy Balance.SingaporeNational University of Singapore2020
     [Google Scholar]
  134. LeonP.V. LoisP.R. VillalonM. PridaE. MorenoM.D. FernøJ. QuiñonesM. MassadiA.O. SeoaneL.M. Novel mechanisms involved in leptin sensitization in obesity.Biochem. Pharmacol.202422311612910.1016/j.bcp.2024.11612938490517
     [Google Scholar]
  135. WangK. WuX. ZhungY. Celastrol directly inhibits PFKM to induce weight loss and leptin sensitization.bioRxiv20202020.0910.1101/2020.09.06.284752
     [Google Scholar]
  136. SmithR.L. SoetersM.R. WüstR.C.I. HoutkooperR.H. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease.Endocr. Rev.201839448951710.1210/er.2017‑0021129697773
     [Google Scholar]
  137. KeshavarzH. Adipose-Derived Molecular Amplification of Glucose Trafficking in the Bloodstream: A Potential New Role for Leptin.Michigan State UniversityUSA2018
     [Google Scholar]
  138. LiebW. SullivanL.M. HarrisT.B. RoubenoffR. BenjaminE.J. LevyD. FoxC.S. WangT.J. WilsonP.W. KannelW.B. VasanR.S. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals.Diabetes Care.200932461261610.2337/dc08‑159619114611
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X356019250118170444
Loading
Leptin Resistance and Cardiometabolic Disorders: Bridging Molecular Pathways, Genetic Variants, and Therapeutic Innovation
Curr. Cardiol. Rev. 21, E1573403X356019 (2025); https://doi.org/10.2174/011573403X356019250118170444
/content/journals/ccr/10.2174/011573403X356019250118170444
/content/journals/ccr/10.2174/011573403X356019250118170444
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): CVD; hypertension; hypothalamus; Leptin; obesity; type 2 diabetes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test